Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
Non-muscle-invasive bladder cancer is labor intensive and costly to manage. Owing to long-term survival rates and life-long monitoring and treatment, it is the most expensive cancer to manage in ...
Findings from an interim analysis of data show that the addition of blue light cystoscopy to conventional white light significantly improved clinical outcomes in a group of patients with ...
Host Rick Bangs’s special guest is Yair Lotan, M.D., a Professor of Urology, Chief of Urologic Oncology, at UT Southwestern Medical Center. When do urologists use a cystoscopy and why? What are the ...
OSLO, Norway, Sept. 15, 2021-- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces a clinical data presentation and highlights from the 2021 American Urological Association Annual Congress ...
KARL STORZ Endoscopy-America, Inc., announces the commercial launch of the PDD Blue Light Flexible Video Cystoscopy System for enhanced detection of non-muscle invasive bladder cancer (NMIBC). This ...
Effects of perioperative chemotherapy on prognosis in muscle invasive bladder cancer treated with radical cystectomy. This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers ...
In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results